Induction of apoptosis in fibroblasts by c-myc protein

doi:10.1016/0092-8674(92)90123-T

Cell

Volume 69, Issue 1, 3 April 1992, Pages 119-128

https://doi.org/10.1016/0092-8674(92)90123-T Get rights and content

Abstract

Although Rat-1 fibroblasts expressing c-myc constitutively are unable to arrest growth in low serum, their numbers do not increase in culture because of substantial cell death. We show this cell death to be dependent upon expression of c-myc protein and to occur by apoptosis. Regions of the c-myc protein required for induction of apoptosis overlap with regions necessary for cotransformation, autoregulation, and inhibition of differentiation, suggesting that the apoptotic function of c-myc protein is related to its other functions. Moreover, cells with higher levels of c-myc protein are more prone to cell death upon serum deprivation. Finally, we demonstrate that deregulated c-myc expression induces apoptosis in cells growth arrested by a variety of means and at various points in the cell cycle.

References (42)

S. Araki et al.
Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation
Bicohem. Biophys. Res. Commun.
(1990)
M. Dean et al.
Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact
J. Biol. Chem.
(1986)
C. Murre et al.
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins
Cell
(1989)
D. Resnitzky et al.
Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation
Cell
(1986)
C.A. Spencer et al.
Control of c-myc regulation in normal and neoplastic cells
Adv. Cancer Res.
(1991)
D. Askew et al.
Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis
Oncogene
(1991)
T.K. Blackwell et al.
Sequence-specific DNA binding by the c-myc protein
Science
(1990)
E.M. Blackwood et al.
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc
Science
(1991)
W. Bursch et al.
The biochemistry of cell death by apoptosis
Biochem. Cell Biol.
(1990)
R. Buttyan et al.
Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland
Mol. Endocrinol.
(1988)

T.G. Cotter et al.

Cell death via apoptosis and its relationship to growth, development and differentation of both tumour and normal cells

Anticancer Res.

(1990)

M. Eilers et al.

Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells

Nature

(1989)

M. Eilers et al.

The Myc protein activates transcription of the alpha-prothymosin gene

EMBO J.

(1991)

J.K. Field et al.

The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review)

Anticancer Res.

(1990)

S.O. Freytag

Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in $G0 G1$

Mol. Cell. Biol.

(1988)

S.O. Freytag et al.

Definition of the activities and properties of c-myc required to inhibit cell differentiation

Cell Growth Diff.

(1990)

R. Heikkila et al.

A c-myc antisense oligodeoxy-nucleotide inhibits entry into S phase but not progress from G0 to G1

Nature

(1987)

D. Hockenbery et al.

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

Nature

(1990)

G.J. Kato et al.

An amino-terminal c-myc domain required for neoplastic transformation activates transcription

Mol. Cell. Biol.

(1990)

N. Kyprianou et al.

Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation

Cancer Res.

(1991)

W.H. Landschulz et al.

The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins

Science

(1988)

Cited by (2921)

Exploring Myc puzzle: Insights into cancer, stem cell biology, and PPI networks
2024, Gene
“The grand orchestrator,” “Universal Amplifier,” “double-edged sword,” and “Undruggable” are just some of the Myc oncogene so-called names. It has been around 40 years since the discovery of the Myc, and it remains in the mainstream of cancer treatment drugs. Myc is part of basic helix–loop–helix leucine zipper (bHLH-LZ) superfamily proteins, and its dysregulation can be seen in many malignant human tumors. It dysregulates critical pathways in cells that are connected to each other, such as proliferation, growth, cell cycle, and cell adhesion, impacts miRNAs action, intercellular metabolism, DNA replication, differentiation, microenvironment regulation, angiogenesis, and metastasis. Myc, surprisingly, is used in stem cell research too. Its family includes three members, MYC, MYCN, and MYCL, and each dysfunction was observed in different cancer types. This review aims to introduce Myc and its function in the body. Besides, Myc deregulatory mechanisms in cancer cells, their intricate aspects will be discussed. We will look at promising drugs and Myc-based therapies. Finally, Myc and its role in stemness, Myc pathways based on PPI network analysis, and future insights will be explained.
A synthetic differentiation circuit in Escherichia coli for suppressing mutant takeover
2024, Cell
Differentiation is crucial for multicellularity. However, it is inherently susceptible to mutant cells that fail to differentiate. These mutants outcompete normal cells by excessive self-renewal. It remains unclear what mechanisms can resist such mutant expansion. Here, we demonstrate a solution by engineering a synthetic differentiation circuit in Escherichia coli that selects against these mutants via a biphasic fitness strategy. The circuit provides tunable production of synthetic analogs of stem, progenitor, and differentiated cells. It resists mutations by coupling differentiation to the production of an essential enzyme, thereby disadvantaging non-differentiating mutants. The circuit selected for and maintained a positive differentiation rate in long-term evolution. Surprisingly, this rate remained constant across vast changes in growth conditions. We found that transit-amplifying cells (fast-growing progenitors) underlie this environmental robustness. Our results provide insight into the stability of differentiation and demonstrate a powerful method for engineering evolutionarily stable multicellular consortia.
Epstein-Barr virus–encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma
2024, Blood
Hematological malignancies such as Burkitt lymphoma (BL), Hodgkin lymphoma (HL), and diffuse large B-cell lymphoma (DLBCL) cause significant morbidity in humans. A substantial number of these lymphomas, particularly HL and DLBCLs have poorer prognosis because of their association with Epstein-Barr virus (EBV). Our earlier studies have shown that EBV-encoded nuclear antigen (EBNA2) upregulates programmed cell death ligand 1 in DLBCL and BLs by downregulating microRNA-34a. Here, we investigated whether EBNA2 affects the inducible costimulator (ICOS) ligand (ICOSL), a molecule required for efficient recognition of tumor cells by T cells through the engagement of ICOS on the latter. In virus-infected and EBNA2-transfected B-lymphoma cells, ICOSL expression was reduced. Our investigation of the molecular mechanisms revealed that this was due to an increase in microRNA-24 (miR-24) by EBNA2. By using ICOSL 3′ untranslated region–luciferase reporter system, we validated that ICOSL is an authentic miR-24 target. Transfection of anti–miR-24 molecules in EBNA2-expressing lymphoma cells reconstituted ICOSL expression and increased tumor immunogenicity in mixed lymphocyte reactions. Because miR-24 is known to target c-MYC, an oncoprotein positively regulated by EBNA2, we analyzed its expression in anti–miR-24 transfected lymphoma cells. Indeed, the reduction of miR-24 in EBNA2-expressing DLBCL further elevated c-MYC and increased apoptosis. Consistent with the in vitro data, EBNA2-positive DLBCL biopsies expressed low ICOSL and high miR-24. We suggest that EBV evades host immune responses through EBNA2 by inducing miR-24 to reduce ICOSL expression, and for simultaneous rheostatic maintenance of proproliferative c-MYC levels. Overall, these data identify miR-24 as a potential therapeutically relevant target in EBV-associated lymphomas.
Decoding the mystery of MMTV-like virus and its relationship with breast cancer metastasis
2023, Journal of Infection and Public Health
MMTV causes mammary tumors in mice, and it is associated with invasive and aggressive forms of breast cancer in humans. However, the underlying mechanisms are yet unknown. We aimed to determine the MMTV-like virus (MMTV-LV) association with histological types of breast cancer, nodal involvement, and metastasis.
First, 105 breast cancer biopsies and 15 disease-free biopsies were collected. Details of clinicopathological characteristics were retrieved from patients’ records. The status of MMTV-LV was already known for these biopsy samples. Associations of MMTV-LV prevalence with LNM status and metastatic history were determined. Next, quantitative PCR (qPCR) was used to quantify env gene mRNA in biopsies positive for MMTV-LV. Expression of the env gene was compared against different histopathological types of mammary tumor, LNM status, and metastasis by performing Ordinary One Way ANOVA followed by Tukey’s multiple comparisons test.
MMTV-LV prevalence was found to have no significant association with LNM or metastatic history. As compared to normal control, expression of the env gene was significantly higher (>2.8 folds) in invasive samples (P-value: < 0.01). Expression was also higher (3.28 and 2.89 folds) in patient samples with LNM (P-value: 0.0006) or metastatic history (P-value: < 0.0001), respectively.
We conclude that MMTV-LV prevalence is not associated with LNM status or breast cancer metastasis; samples with invasive phenotypes, nodal involvement, and metastasis exhibit significantly higher expression of the MMTV-like env gene.
Upregulation of ribosome biogenesis via canonical E-boxes is required for Myc-driven proliferation
2022, Developmental Cell
The transcription factor Myc drives cell growth across animal phyla and is activated in most forms of human cancer. However, it is unclear which Myc target genes need to be regulated to induce growth and whether multiple targets act additively or if induction of each target is individually necessary. Here, we identified Myc target genes whose regulation is conserved between humans and flies and deleted Myc-binding sites (E-boxes) in the promoters of fourteen of these genes in Drosophila. E-box mutants of essential genes were homozygous viable, indicating that the E-boxes are not required for basal expression. Eight E-box mutations led to Myc-like phenotypes; the strongest mutant, ppan^Ebox−/−, also made the flies resistant to Myc-induced cell growth without affecting Myc-induced apoptosis. The ppan^Ebox−/− flies are healthy and display only a minor developmental delay, suggesting that it may be possible to treat or prevent tumorigenesis by targeting individual downstream targets of Myc.
ANGPTL4 regulates ovarian cancer progression by activating the ERK1/2 pathway
2024, Cancer Cell International

View all citing articles on Scopus

View full text

Cell

ArticleInduction of apoptosis in fibroblasts by c-myc protein

Abstract

Bicohem. Biophys. Res. Commun.

J. Biol. Chem.

Cell

Cell

Adv. Cancer Res.

Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis

Oncogene

Sequence-specific DNA binding by the c-myc protein

Science

Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc

Science

The biochemistry of cell death by apoptosis

Biochem. Cell Biol.

Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland

Mol. Endocrinol.

Cell death via apoptosis and its relationship to growth, development and differentation of both tumour and normal cells

Anticancer Res.

Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells

Nature

The Myc protein activates transcription of the alpha-prothymosin gene

EMBO J.

The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review)

Anticancer Res.

Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0G1

Mol. Cell. Biol.

Definition of the activities and properties of c-myc required to inhibit cell differentiation

Cell Growth Diff.

A c-myc antisense oligodeoxy-nucleotide inhibits entry into S phase but not progress from G0 to G1

Nature

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

Nature

An amino-terminal c-myc domain required for neoplastic transformation activates transcription

Mol. Cell. Biol.

Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation

Cancer Res.

The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins

Science

Article
Induction of apoptosis in fibroblasts by c-myc protein

Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in $G0 G1$